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Abstract 15 
Purpose. To investigate the absorption curve and acute effects of caffeine at rest in 16 
individuals with no spinal cord injury (SCI), paraplegia (PARA) and tetraplegia (TETRA). 17 
Methods. Twenty-four healthy males (8 able-bodied (AB), 8 PARA and 8 TETRA) 18 
consumed 3 mg∙kg-1 caffeine anhydrous (CAF) in a fasted state. Plasma caffeine [CAF], 19 
glucose, lactate, free-fatty acid [FFA] and catecholamine concentrations were measured 20 
during a 150 min rest period. Results. Peak [CAF] was greater in TETRA (21.5 µM) 21 
compared to AB (12.2 µM) and PARA (15.1 µM), and mean peak [CAF] occurred at 70, 80 22 
and 80 min, respectively. Moderate and large ES were revealed for TETRA compared to 23 
PARA and AB (-0.55 and -1.14, respectively) for the total area under the [CAF] versus time 24 
curve. Large inter-individual responses were apparent in SCI groups. The change in plasma 25 
catecholamine concentrations following CAF did not reach significance (p>0.05) however 26 
both adrenaline and noradrenaline concentrations were lowest in TETRA. Significant 27 
increases in [FFA] were seen over time (p<0.0005) but there was no significant influence of 28 
SCI level. Blood lactate concentration reduced over time (p=0.022) whereas blood glucose 29 
concentration decreased modestly (p=0.695), and no difference between groups was seen 30 
(p>0.05). Conclusion. Level of SCI influenced the caffeine absorption curve and there was 31 
large inter-individual variation within and between groups. Individual curves should be 32 
considered when using caffeine as an ergogenic aid in athletes with an SCI. The results 33 
indicate TETRA should trial low doses in training and PARA may consider consuming 34 
caffeine greater than 60 min prior to exercise performance. The study also supports caffeine’s 35 
direct effect on adipose tissue, which is not secondary to catecholamine release. 36 
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Introduction 38 
Supplementation with caffeine (3-6 mg∙kg-1) can improve long and short-term endurance 39 
performance (7,9) in able-bodied (AB) participants. However, there is a paucity of research 40 
on the effects of caffeine on exercise performance in physically impaired populations e.g. 41 
persons with a spinal cord injury (SCI). While current evidence is equivocal, a beneficial 42 
effect of caffeine (4-6 mg∙kg-1 body mass (BM) in capsule form) on short-term wheelchair 43 
propulsion exercise has been reported (5,13). These studies highlighted that there was great 44 
inter-individual variability in wheelchair performance responses during a 1500 m time trial, 4 45 
min maximal push and repeated sprints, especially in individuals with an SCI. The authors 46 
highlighted the potential for slower caffeine absorption due to delayed gastrointestinal (GI) 47 
transit times and prolonged gastric emptying (GE), especially in those with a cervical lesion 48 
level (18). Understanding an individual’s time to peak caffeine concentration has been shown 49 
to have little impact on prolonged AB endurance cycling performance (34) but is likely to be 50 
important prior to short-term upper-body exercise (UBE), and may require further 51 
consideration in persons with an SCI. 52 
Both metabolic and physiological functions are altered in individuals with an SCI, and the 53 
level and completeness of injury has been shown to influence drug pharmacokinetics (15,23). 54 
A review of the literature by Mestre et al. (23) indicated that the delayed absorption seen in 55 
some individuals with an SCI increased the time to achieve the required therapeutic dose. 56 
One drug reportedly affected by delayed GE and decreased GI motility is theophylline (32), 57 
which can be used by individuals with an SCI to help treat bradycardia or to promote the 58 
recovery of hemidiaphragmatic function. Diminished bioavailability could result in 59 
underestimating the load and maintenance dose of theophylline in individuals with tetraplegia 60 
(32). As a methylxanthine drug, theophylline has similar pharmacodynamic actions to 61 
caffeine (28) and it has also been linked to improved endurance performance (14,22). There 62 
is therefore reason to believe that caffeine absorption may also be delayed in persons with an 63 
SCI. In disagreement however, Van Soeren et al. (37) suggested that the time to peak caffeine 64 
concentration (6 mg∙kg-1) in individuals with tetraplegia (~47 µM at 40 min (n=6)) did not 65 
differ to those of AB individuals. The authors however could not assess the influence of SCI 66 
lesion level on caffeine absorption because there was no direct control group and only two 67 
individuals with paraplegia. They also did not report individual participant data, which may 68 
help to explain inter-individual performance responses. Flueck et al. (4) measured plasma 69 
caffeine concentrations (median) at 60 min only in AB individuals (45.1 µmol∙L-1) and 70 
individuals with paraplegia (~54 µmol∙L-1) and tetraplegia (66.1 µmol∙L-1). It therefore 71 
remains difficult to determine whether the time course of caffeine absorption differs based on 72 
an individual’s SCI level. 73 
Numerous mechanisms of action have been proposed to help explain the beneficial effects of 74 
an acute dose of caffeine on exercise performance. Current research suggests the main 75 
mechanism at physiological caffeine doses is the blockade of central nervous system (CNS) 76 
adenosine receptors, which indirectly effects affects neurotransmitter release (19) to increase 77 
arousal, alertness and attention. Individuals with tetraplegia are therefore an interesting study 78 
population given the reduced sympathetic activity caudal to the lesion level and associated 79 
impaired catecholamine response (27). The study of this population has lent support to the 80 
hypothesis that caffeine can have a direct effect on tissues following reports of adrenaline-81 
independent free fatty acid (FFA) mobilisation (37). No study has directly investigated the 82 
acute effects of caffeine in a group of individuals with no SCI, paraplegia and tetraplegia. 83 
Hence, the current study aimed to explore the time course of caffeine absorption and its 84 
effects at rest in these three groups, with the aim of providing safe and accurate 85 
recommendations for its use as an ergogenic aid by individuals with an SCI. It wais 86 
hypothesised that caffeine absorption will be delayed in individuals with tetraplegia 87 
compared to those with paraplegia and no SCI. 88 
Methods 89 
Participants. Twenty-four healthy recreationally active males (8 able-bodied controls (AB), 90 
8 individuals with paraplegia (PARA) and 8 with tetraplegia (TETRA)) provided informed 91 
consent to participate in the current study. Participants were classified using the American 92 
Spinal Injury Association (ASIA) scale (20). A health screening questionnaire was completed 93 
by all participants and individuals were excluded if any of their medication had known 94 
interactions with caffeine. Average daily caffeine intake was assessed using a modified 95 
version of the caffeine consumption questionnaire (21). All procedures were approved by the 96 
University Ethical Advisory Committee and performed following the Declaration of Helsinki. 97 
Participants’ characteristics are shown in Table 1.  98 
Procedures. In the days prior to visiting the laboratory, participants maintained their normal 99 
dietary and activity patterns (light-moderate intensity exercise only) and their individual 100 
medication regimes. Participants were provided with a list of caffeine containing foods and 101 
drinks, and were asked to abstain from consumption in the 36 h preceding their laboratory 102 
visit. Participants were also asked to refrain from alcohol consumption for 24 h prior to their 103 
visit. 104 
Participants arrived at the laboratory (between 08:00 and -10:.00) after fasting from 21:00 the 105 
previous eveningin afollowing an overnight fast fasted state(no food intake after 21:00). 106 
Water consumption was encouraged to help ensure the participant arrived euhydrated. On 107 
arrival participants were asked to void their bladder, if necessary, prior to lying in a semi-108 
supine position on a laboratory bed. Participants were asked to report any side-effects to the 109 
investigators immediately at any point during the trial. A cannula (Venflon, Becton 110 
Dickinson, Helsinborg, Sweden) was inserted into an antecubital vein for subsequent venous 111 
sampling. The cannula was kept patent using 5-10 ml sodium chloride (0.9%) after each 112 
blood sample.  113 
After a minimum of 15 min rest, a baseline venous blood sample was taken. Participants then 114 
consumed cellulose capsules (Bulk Powders, Colchester, UK) containing 3 mg∙kg-1 BM 115 
caffeine anhydrous (My Protein, Northwich, UK), which were filled manually by the 116 
investigators to the nearest 0.1 mg.  Participants remained rested for 150 min during which a 117 
further 9 blood samples were taken. The blood sampling schedule can be seen in Figure 1. 118 
After the final blood sample, participants were again asked once more to record whether they 119 
experienced any side-effects during the experimental trial. 120 
Blood sampling and analysis. Blood samples were immediately separated into tubes that 121 
contained the relevant preservative(s). At every sampling time-point 5 ml blood was added to 122 
an EDTA K2 vacutainer for subsequent plasma caffeine concentration ([CAF]) analysis. A 20 123 
µl blood sample was removed and analysed in duplicate for blood lactate ([BLa]) and glucose 124 
([GLU]) concentrations using an automatic analyser (Biosen C-Line, EKF Diagnostic GmbH, 125 
Barleben, Germany).  For catecholamine and FFA analysis (baseline, 60, 90 and 150 min), a 126 
further 10 ml of blood was dispensed into two lithium-heparin tubes containing 37.5 µl of 127 
EGTA-Glutathione for the subsequent analysis of plasma adrenaline ([A]), noradrenaline 128 
([NA]) and FFA ([FFA]) concentrations. In addition, 25 µl of 3 mg∙ml-1 tetrahydrolipstatin 129 
(THL) was added to the tube for [FFA] analysis. All tubes were centrifuged at 1000g for 10 130 
min at 4ºC as previously described (12). Plasma samples were aliquoted into Eppendorfs and 131 
stored at -80ºC until analysis. 132 
Plasma [CAF] was analysed using high-performance liquid chromatography (HPLC) as 133 
described by Holland et al. (16) with the following minor modifications; prior to injection 134 
onto the HPLC column each sample was individually filtered (Mini-UniPrep syringeless 135 
filters, Fisher Scientific, UK) and no guard column was used. The method produced a 136 
coefficient of variation (CV) of 1.06% (range 0.24-1.45%).  137 
Plasma [A] and [NA] were also determined using HPLC as previously described by Forster & 138 
Macdonald (6). A plasma volume of 500 µl was used for analysis. The method produced CVs 139 
of 0.31 and 0.17% for [A] and [NA] respectively.  140 
Plasma was analysed enzymatically for [FFA] using an in vitro enzymatic colorimetric 141 
method (Wako Instrument kit) and a Pentra 400 analyser (Horiba Medical, California, USA). 142 
The method produced an intra-assay CV of 1.68 and 1.28% for high and low FFA quality 143 
controls (QC) (4 repeats of the QC samples at intervals during the analysis).  144 
Statistical analyses  145 
Data were analysed using the IBM Statistics Software Package for the Social Sciences (SPSS) 146 
version 22 (IBM Corporation, New York, USA). The trapezium rule was used to calculate the 147 
total area under the variable versus time curve for [CAF] (TAUC-CAF), [FFA] (TAUC-FFA), 148 
[A] (TAUC-A) and [NA] (TAUC-NA). The incremental area under the plasma concentration 149 
versus time curve for [FFA] (iAUC-FFA), [A] (iAUC-A) and [NA] (iAUC-NA) was also 150 
calculated using the same method after adjusting for baseline concentrations.  151 
Normal distribution was checked using Shapiro-Wilk tests and the data are presented as mean 152 
± SD. Data for [FFA] were not normally distributed and were log transformed prior to 153 
analysis. These data are presented as geometric mean (95% confidence intervals (CI)) and 154 
analysis is based on the ratios of geometric means and 95% CI for ratios. Homegeneity of 155 
variances was confirmed by Mauchly’s test of sphericity, and where the sphericity 156 
assumption was violated, the Greenhouse Geisser correction was applied to the degrees of 157 
freedom. 158 
Repeated measures analysis of variance (ANOVA) for group and time were used to examine 159 
differences between [FFA], [A], [NA], [Bla] and [GLU].  160 
An analysis of covariance (ANCOVA) was used to examine differences between [CAF], with 161 
daily caffeine consumption (low <50 mg·d-1, moderate 50-250 mg·d-1 and high >250 mg·d-1) 162 
as a covariate. One-way repeated measures ANOVAs were used to analyse TAUC and iAUC 163 
data. Planned simple and difference contrasts were applied to explain any significant results.  164 
Statistical significance was accepted at p ≤ 0.05 and absolute standardised effect sizes (ES) 165 
are included to supplement important findings. An ES of 0.2 was considered small, 0.5 166 
moderate and 0.8 large according to Cohen (3). Due to incomplete data sets (e.g. insufficient 167 
blood flow or a cannula change) the number of participants included in each analysis differs. 168 
Data sets were A (7/6/7), NA (7/7/8), FFA (7/7/7), Bla (5/5/6) and GLU (8/6/8) for AB, 169 
PARA and TETRA groups, respectively.  170 
Power analysis was performed using the [CAF] observed in 3 groups of participants with no 171 
SCI, paraplegia and tetraplegia 60 min post-ingestion of 6 mg∙kg-1 caffeine (46.4 (6.8), 55.3 172 
(19.8) and 64.1 (6.9) µM, respectively) (4). The a priori analysis, conducted in G*Power 3.1, 173 
revealed that six participants would be required in each group to detect a similar change in 174 
[CAF] with ES of 0.59, 0.66 and 2.74 (4), 90% power, and an α of 5%. Given the novel 175 
nature of this investigation and the heterogeneity of the population, an additional two 176 
participants per group were recruited to increase statistical power (n = 8). 177 
Results 178 
Plasma caffeine  179 
At baseline, [CAF] was either undetectable or very low, which indicates that all participants 180 
adhered to the withdrawal guidelines. Differences over time and across groups were revealed 181 
(main effect time p < 0.0005; main effect group p = 0.026; time by SCI level interaction p = 182 
0.019) (Figure 2). Planned simple contrasts revealed these group differences occurred 183 
between AB and TETRA (p = 0.017), whereas no difference was observed between AB and 184 
PARA (p=0.913). Peak [CAF] in TETRA was significantly greater than AB (p = 0.008) yet 185 
non-significantly (p = 0.058), but meaningfully (ES = 0.9) greater than PARA (21.5 ± 7.0, 186 
12.2 ± 2.3 and 15.1 ± 8.1 µM, respectively). Time to peak [CAF] varied greatly between 187 
individuals but group means were 80 min for AB and PARA, and 70 min for TETRA. There 188 
was no influence of habitual caffeine use on [CAF] (p = 0.943). 189 
No significant difference in TAUC-CAF was observed between groups (p = 0.135; AB 3.74 ± 190 
0.96 µM, PARA 4.62 ± 3.12 µM, and TETRA 6.08 ± 2.15 µM). However, small (AB vs. 191 
PARA, ES = 0.38), moderate (PARA vs. TETRA, ES = 0.55) and large (AB vs. TETRA, ES 192 
= 1.14) ES were apparent. 193 
Seven participants (3 AB/2 PARA/2 TETRA) reported adverse effects prior to/during the first 194 
30 min of testing (headache/light-headed (2)) and during testing, (struggling with quick 195 
decision making (1), tingling arm (1), twitching eye (1)) and five participants reported feeling 196 
more alert. 197 
Plasma catecholamines (adrenaline and noradrenaline) 198 
All catecholamine analysis excluded the participant with a T4 lesion level due to a missed 199 
sample and hence statistical analysis for PARA was calculated based on injuries at or below 200 
T6/7. The change in [A] over the course of the resting protocol did not reach statistical 201 
significance, but did differ between groups (main effect of time p = 0.088; main effect of 202 
group p = 0.027; time by SCI level p = 0.618) (Figure 3). Planned difference contrasts 203 
revealed these group differences occurred between PARA and TETRA (p = 0.019) only. 204 
There was no significant difference in TAUC-A (p = 0.075) between groups (AB 0.43 ± 0.17 205 
nmol·L-1, PARA 0.57 ± 0.22 nmol·L-1, and TETRA 0.22 ± 0.10 nmol·L-1) though ES were 206 
large for both AB (ES = 2.02) and PARA (ES = 1.04) compared to TETRA. There was no 207 
difference in iAUC-A (p = 0.733). 208 
The [NA] did not change significantly during the 150 min protocol (p = 0.423) but did differ 209 
between groups (p = 0.003), and no interaction was evident (p = 0.772). Planned difference 210 
contrasts revealed these group differences occurred between AB and TETRA (p = 0.001), and 211 
PARA and TETRA (p = 0.006), but no significant difference was observed between AB and 212 
PARA (p = 0.505). There was a significant difference in TAUC-NA (p = 0.003) between 213 
groups (AB 4.04 ± 0.92 nmol·L-1, PARA 3.68 ± 1.01 nmol·L-1, and TETRA 2.01 ± 1.21 214 
nmol·L-1). Small (AB vs. PARA, ES = 0.38) and large (AB vs. TETRA, ES = 1.89, and 215 
PARA vs. TETRA, ES = 1.50) ES were revealed. However, no significant difference in 216 
iAUC-NA was observed (p = 0.827). 217 
Plasma FFA, lactate and glucose  218 
Differences in [FFA] were observed over time and between groups, with the latter not 219 
reaching significance, but displaying a large effect however the latter failed to reach 220 
significance (ES = 0.80) (main effect time p < 0.0005; main effect group p = 0.054; time by 221 
group interaction p = 0.035). Means (95% CI) [FFA] wereas 51% (-42 to -24%), 64% (-47 to 222 
-30%) and 84% (-54 to -37%) higher than baseline at 60, 90 and 150 min, respectively. 223 
Geometric mMeans (95% CI) [FFA] wereas 26% (-46 to 2%) lower in PARA than AB, but 224 
and 9% higher than AB in PARA (95% CI -2-46 to 862%) in and TETRA than AB (95% CI -225 
34 21 to 2750%), respectively;. furthermore, Mean [FFA] results wasere 47% (6 to 103%) 226 
higher in TETRA thancompared to PARA (95% CI -516 to -6103%) (Figure 3). The 227 
interaction indicated that while PARA experienced only a marginal increase in [FFA] from 228 
baseline to 150 min (Δ ~0.13 mmol·l-1), AB and TETRA increased to a greater extent over 229 
the course of the protocol (Δ ~0.36 and 0.31 mmol·l-1, respectively).  230 
Although the main effect for No significant differences in TAUC-FFA was not 231 
significantobserved (p = 0.072), the effect sizes ranged from small yet moderate (AB vs. 232 
PARA, ES = 0.47, AB vs. TETRA, ES = 0.85) toand large (AB vs. TETRA, ES = 0.85; 233 
PARA vs. TETRA, ES = 1.16) ES were revealed. No significant difference in iAUC-FFA 234 
was observed (p = 0.357). 235 
Differences in [Bla] were observed over time but not between groups (main effect time p = 236 
0.022; main effect group p = 0.463; time by group interaction p = 0.065). Planned difference 237 
contrasts revealed a significant decrease in [Bla] between baseline and 60 min (p = 0.049), 238 
and between 90 and 150 min (p < 0.0005). No significant difference in [GLU] was seen over 239 
the course of the 150 min protocol (p = 0.695) or between groups (p = 0.983).  240 
Discussion 241 
The current study is the first to report large inter-individual differences in caffeine absorption 242 
within and between groups when separated for level of SCI (AB, PARA and TETRA). 243 
Consequently, dosage and timing recommendations provided to individuals with an SCI may 244 
need to be adapted from the AB literature. In addition, the pattern of caffeine absorption 245 
differs in TETRA compared to AB and PARA. There were small differences in [A], [NA] 246 
and [FFA] between the AB and SCI groups, which were non-significant when baseline values 247 
were accounted for using the incremental area under the curve. No differences in [Bla] and 248 
[GLU] were seen between groups.  249 
Plasma caffeine  250 
Participant’s [CAF] increased in all three groups following the ingestion of 3 mg∙kg-1 caffeine. 251 
The [CAF] in AB at 60 min (10.8 ± 3.1 µM) is in line with that reported 60 min post-252 
ingestion of 2, 3 and 4 mg∙kg-1 caffeine (5.7, ~15 and 14.6 µM, respectively) (11,33). This 253 
study is the first to investigate the caffeine absorption curve in a group of participants with 254 
paraplegia. In agreement with the hypothesis, the PARA results do not differ from the AB 255 
responses at 60 min (11.1 ± 7.9 µM) and both groups reached mean peak [CAF] at 80 min. 256 
The TETRA responses were significantly greater than AB and the mean peak [CAF] was 257 
reached 10 min earlier (70 min). Flueck et al. (4) also reported a higher [CAF] 60 min post-258 
ingestion of ~6 mg∙kg-1 caffeine in individuals with tetraplegia compared to those with 259 
paraplegia (66.1 and 45.1 µM, respectively). Interestingly, Van Soeren et al. (37) also 260 
reported a high peak [CAF] of 46.7 ± 5.0 µM in individuals with tetraplegia (n=6) yet this 261 
was reached after only 40 min post-ingestion of 6 mg∙kg-1 caffeine. The current study 262 
therefore adds further support to reports of higher [CAF] in TETRA compared to individuals 263 
with lower lesion levels and no spinal injury. Furthermore, the data also highlight the large 264 
variability that exists within each group. Based on the current study there does not appear to 265 
be an influence of habitual caffeine use on the participants’ [CAF] in response to a single 266 
dose, as seen previously (1). Seven participants reported adverse effects which were likely a 267 
result of withdrawal (headache), fasting (light headed) and CAF (tingling arm, twitching eye 268 
and struggling to make quick decisions). All symptoms were mild and only lasted for a short 269 
duration. The 3 mg∙kg-1 caffeine dose is therefore deemed safe in this population. 270 
An interaction effect occurred due to the sharp increase in [CAF] in TETRA while both AB 271 
and PARA groups [CAF] increased gradually followed by a plateau. The rapid increase in 272 
[CAF] in TETRA means that the hypothesis of slowed absorption in this population can be 273 
rejected. The sharp rise may be due to a number of factors. Firstly, individuals with 274 
tetraplegia have a smaller blood volume compared to AB individuals (17) due to atrophy of 275 
the musculature and vessels of the lower limbs. This reduced blood volume may result in a 276 
falsely large [CAF] in TETRA following the administration of a standardised dose per 277 
kilogram body mass. Secondly, following a cervical or thoracic SCI sympathetic outflow to 278 
the liver is also disrupted, which in turn can lead to hepatic pathology (30). The liver is 279 
innervated by both sympathetic and parasympathetic nerves, and the sympathetic splanchnic 280 
nerves originate from neurons which are located in the spinal column (T7-T12) (38). Acute 281 
changes to the liver occur due to the complete (cervical level) and partial (thoracic level) 282 
disruption to the descending control of sympathetic neurons innervating the organ (30). It has 283 
been proposed that abnormal liver function may affect the metabolism and bioavailability of 284 
drugs (23,30). The half-life of many drugs can be prolonged in individuals with an SCI who 285 
display suboptimal liver function and slow renal clearance (23,30). Serum caffeine half-life 286 
has also been shown to be severely prolonged in individuals with compromised liver function 287 
e.g. those with alcoholic hepatic liver disease (36). The half-life of caffeine in healthy 288 
individuals is ~4-6 h (1). This may help explain the sharp rise to peak [CAF] in TETRA 289 
(slowed metabolism) which remains higher than AB and PARA (slowed renal clearance). 290 
This TETRA response indicates that individuals with a cervical SCI may consider using a 291 
lower dose of caffeine to produce similar [CAF] as AB and PARA while avoiding any 292 
potential side-effects that are reported anecdotally and in previous research (13). It also 293 
suggests that individuals with a high lesion level may need to consider reducing the 294 
frequency of caffeine intake to prevent the potential negative effects of high doses of caffeine 295 
e.g. nervousness, jitters, restlessness, sleeplessness and irritability.  296 
The TAUC-CAF did not statistically differ between groups yet a large ES of 1.14 was evident 297 
between AB and TETRA. Large inter-individual responses were evident in both SCI groups 298 
(Figure 2) due to the heterogeneous nature of this population. The equivocal findings 299 
regarding the beneficial effects of caffeine during short-term exercise performance (4) may 300 
be partly explained by these inter-individual differences, highlighted by the current PARA 301 
and TETRA responses. Examination of individual data within PARA reveals some interesting 302 
findings. Participant 9 (L1 lesion; ASIA B) produced a similar curve to the AB participants, 303 
with a peak (albeit larger) at 45 min followed by a steady decline. However, caffeine did not 304 
appear in the bloodstream of participant 10 (T7 lesion; ASIA B) until 70 min and continued 305 
to rise for the remaining 80 min. Hence the implementation of a standard caffeine protocol 306 
whereby caffeine is administered 60 min prior to short-term exercise performance would 307 
result in participant 10 exhibiting a [CAF] associated with a placebo dose at the 308 
commencement of exercise. For short-term exercise performance it is therefore recommended 309 
that an athlete with an SCI determines their individual absorption curve to produce 310 
individualised dose and timing recommendations. If this is impractical it is recommended that 311 
caffeine is provided to individuals with paraplegia earlier to ensure it enters the bloodstream 312 
prior to exercise performance. Research into the use of caffeine gum or mouth rinse is 313 
emerging yet the evidence of a consistent positive effect is currently limited (26,29). 314 
Consuming caffeine in this format allows direct absorption into the bloodstream through the 315 
buccal mucosa and may eliminate any potential issues regarding caffeine absorption in 316 
individuals with an SCI.  317 
Body mass and habitual caffeine intakes were similar between all three groups, but PARA 318 
were significantly older than AB (Table 1). However, previous research has suggested that 319 
age is not associated (p > 0.612) with Cmax or time to Cmax following caffeine ingestion 320 
(Skinner et al., 2014) nor does it affect gastric emptying (Kao et al., 1999).  Furthermore, no 321 
significant correlations were observed between age and Cmax (r = 0.07) or time to Cmax (r = -322 
0.11) within the current cohort. 323 
Plasma catecholamines (adrenaline and noradrenaline) 324 
Resting plasma catecholamine concentrations did not significantly increase over the course of 325 
the 150 min protocol in any group (Figure 3). In contrast, Flueck et al. (4) and Van Soeren et 326 
al. (37) reported increases in adrenaline in both AB individuals and individuals with 327 
paraplegia, which may in part be due to the larger 6 mg∙kg-1 dose administered in these 328 
studies. In line with previous findings, baseline catecholamine concentrations were lower in 329 
TETRA compared to AB and PARA due to the impaired sympathetic activation of the 330 
nervous system (27,31). 331 
Plasma FFA, lactate and glucose 332 
Mean resting [FFA] increased over time from 0.36 ± 0.19 mmol∙L-1 at baseline to 0.61 ± 0.25 333 
at 150 min, in agreement with previous research in an AB and SCI population (10,37). In the 334 
absence of a catecholamine response, the current results lend further support for a direct 335 
effect of caffeine on human tissue, specifically adipocytes. The majority of research suggests 336 
that FFA availability does not result in greater FFA oxidation and therefore does not alter 337 
substrate use at rest or during exercise (12,24). It is also unlikely to aid performance during 338 
short-term upper-body exercise where participants/athletes predominantly work anaerobically, 339 
and therefore utilise carbohydrate as the main substrate.  340 
Baseline [FFA] was higher in TETRA than AB or PARA (Figure 3). The lack of muscle 341 
innervation of paralysed lower limbs in individuals with an SCI leads to rapid muscle atrophy 342 
and a reduction in resting metabolic rate (25). Alongside poor nutritional choices and a 343 
disruption in the secretion of anabolic hormones, these changes can result in an increase in fat 344 
mass (35). An expanding fat mass which releases more FFA and a potential reduction in FFA 345 
clearance leads to increased plasma [FFA] (2). The [FFA] responses only significantly 346 
differed between the two SCI groups (PARA vs. TETRA). One possible explanation for this 347 
could be the difference in the group’s time since injury (PARA 4.3 ± 4.3 yr and TETRA 12.2 348 
± 6.3 yr) which has been positively associated with loss of lean tissue and increased fat mass 349 
(35). Unfortunately no body composition or respiratory exchange ratio (RER) data were 350 
collected to enable a greater understanding of the [FFA] responses and whether substrate use 351 
was influenced at rest. However, previous research would suggest this does not occur (12,37).  352 
Many studies report an increase in [Bla] during exercise following the ingestion of caffeine, 353 
sometimes in the absence of increased workload/speed/power. At rest however, the current 354 
data show [Bla] decreased slightly over the course of the 150 min protocol, which is in line 355 
with previous data (37). On the other hand, [GLU] decreased modestly (non-significantly) 356 
during the current protocol, as previously reported (24) and is unlikely a result of caffeine 357 
ingestion. 358 
Conclusion 359 
The current study demonstrates that there is large inter-individual variability in caffeine 360 
absorption in individuals with an SCI and that this should be assessed prior to making 361 
specific recommendations for its use. Individuals with tetraplegia may consider using a lower 362 
dose and individuals with paraplegia may consider consuming supplementary caffeine earlier 363 
than the 60 min recommended to AB individuals.  364 
Acknowledgements 365 
The authors would like to thank all the participants for taking part in the study, the University 366 
of Nottingham School of Life Sciences for performing the plasma catecholamine and free 367 
fatty acid concentration analysis, and The Peter Harrison Centre for Disability Sport for their 368 
support. 369 
Conflicts of interest 370 
The authors declare no conflict of interest. The results of the present study do not constitute 371 
endorsement by ACSM. The authors declare that the results of the study are presented clearly, 372 
honestly, and without fabrication, falsification, or inappropriate data manipulation. 373 
 374 
References 375 
1. Bell DG, McLellan TM. Exercise endurance 1, 3, and 6 h after caffeine ingestion in 376 
caffeine users and nonusers. J Appl Physiol. 2002;93:1227-1234. 377 
2. Bjorntorp P, Bergman H, Varnauskas E. Plasma free fatty acid turnover rate in obesity. 378 
Act Med Scand. 1969;185:351-356.  379 
3. Cohen JA. A power primer.  Psychol Bulletin. 1992;112(1):155-159. 380 
4. Flueck JL, Lienert M, Schaufelberger F, Krebs J, Perret C. Ergogenic effects of 381 
caffeine consumption in a 3 min all-out arm crank test in paraplegic and tetraplegic 382 
compared to able-bodied individuals. Int J Sport Nutr Ex Metab. 2015;25(6):584-593. 383 
5. Flueck JL, Mettler S, Perret C. Influence of caffeine and sodium citrate ingestion on 384 
1500 m exercise performance in elite wheelchair athlete: A pilot study. Int J Sport 385 
Nutr Exerc Metab. 2014;24:296-304. 386 
6. Forster CD, Macdonald IA. The assay of the catecholamine content of small volumes 387 
of human plasma. Biomed Chromatogr. 1999;13:209-215. 388 
7. Ganio MS, Klau JF, Casa DJ, Armstrong LE, Maresh CM. Effect of caffeine on sport-389 
specific endurance performance: a systematic review. J Strength Cond Res.  390 
2009;23(1):315-324. 391 
8. Gorgey AS, Wells KM, Austin TL. Adiposity and spinal cord injury. World J Orthop. 392 
2015;6(8):567-576. 393 
9. Graham TE. Caffeine and exercise: metabolism, endurance and performance. Sports 394 
Med. 2001;31(11):785-807. 395 
10. Graham TE, Helge JW, MacLean DA, Kiens B, Richter EA. Carbohydrate ingestion 396 
does not alter carbohydrate or fat metabolism in human skeletal muscle during 397 
exercise. J Physiol. 2000;529(3):837-847. 398 
11. Graham TE, Spriet LL. Performance and metabolic response to a high caffeine dose 399 
during prolonged exercise. J Appl Physiol. 1995;71(6):2292-2298. 400 
12. Graham TE, Spriet LL. Metabolic, catecholamine, and exercise performance 401 
responses to various doses of caffeine. J Appl Physiol. 1991;78(3):867-874. 402 
13. Graham-Paulson TS, Perret C, Watson P, Goosey-Tolfrey VL. Improvement in sprint 403 
performance in wheelchair sportsmen with caffeine supplementation. Int J Sport 404 
Physiol Perform. 2015;11(2):214-220. 405 
14. Greer F, Friars D, Graham TE. Comparison of caffeine and theophylline ingestion: 406 
exercise metabolism and endurance. J Appl Physiol. 2000;89:1837-1844. 407 
15. Halstead LS. Feldman S, Claus-Walker J, Patel VC. Drug absorption in spinal cord 408 
injury. Arch Phys Med Rehab. 1985;66(5):298-301. 409 
16. Holland DT, Godfredsen KA, Page T, Connor JD. Simple high-performance liquid 410 
chromatography method for the simultaneous determination of serum caffeine and 411 
paraxanthine following rapid sample preparation. J Chromatogr B. 1991;707:105-110. 412 
17. Houtman S, Oeseburg B, Hopman MTE. Blood volume and haemoglobin after spinal 413 
cord injury. Am J Physical Med Rehab, 2000;79:260-265. 414 
18. Kao C, Ho Y, Changlai S, Ding H. Gastric emptying in spinal cord injury patients. 415 
Digest Dis Sci. 1999;44:1512-1515. 416 
19. Keisler BD, Armsey TD. Caffeine as an ergogenic aid. Curr Sports Med Rep. 417 
2006;5:168-177. 418 
20. Kirschblum SC, Burns, SP, Biering-Sorensen F. International standards for 419 
neurological classification of spinal cord injury (revised 2011). J Spinal Cord Med. 420 
2011;34:535-546. 421 
21. Landrum RE. College students' use of caffeine and its relationship to personality. Coll 422 
Stud J. 1992;26:151–155. 423 
22. Marsh GD, McFadden RG, Nicholson RL, Leasa DJ, Thompson TR. Theophylline 424 
delays skeletal muscle fatigue during progressive exercise. Am J Respir Crit Care 425 
Med. 1993;147(4):876-879. 426 
23. Mestre H, Alkon T, Salazar S, Ibarra A. Spinal cord injury sequelae alter drug 427 
pharmacokinetics: an overview. Int Spinal Cord Soc. 2011;49:955-960. 428 
24. Mohr T, Van Soeren M, Graham TE, Kjaer M. Caffeine ingestion and metabolic 429 
responses of tetraplegic humans during electrical cycling. J Appl Physiol. 430 
1998;85:979-985. 431 
25. Monroe MB, Tataranni PA, Pratley R, Manore MM, Skinner JS, Ravussin E. Lower 432 
daily energy expenditure as measured by a respiratory chamber in subjects with spinal 433 
cord injury compared with control subjects. Am J Clin Nutr, 1998;68:1223-1227. 434 
26. Paton C, Costa V Guglielmo L. Effects of caffeine chewing gum on race performance 435 
and physiology in male and female cyclists. J Sport Sci. 2015;10:1076-1083. 436 
27. Paulson TAW, Goosey-Tolfrey VL, Lenton JP, Leicht CA, Bishop NC. Spinal cord 437 
injury level and the circulating cytokine response to strenuous exercise. Med Sci 438 
Sports Exerc. 2013;45(9):1649-1655. 439 
28. Raguso CA, Coggan AR, Sidossis LS, Gastaldelli A, Wolfe RR. Effect of 440 
theophylline on substrate metabolism during exercise. Metab. 1996;45(9):1153-1160. 441 
29. Ryan WJ, Kim C-H, Muller MD. Low-dose caffeine administered in chewing gum 442 
does not enhance cycling to exhaustion. J Str Cond Res. 2012;26)3):844-850. 443 
30. Sauerbeck AD, Laws L, Bandara VVR, Popovich PG, Haughey NJ, McTiguue DM. 444 
Spinal cord injury causes chronic liver pathology in rats. J Neurotrauma. 445 
2015;32:159-169. 446 
31. Schmid A, Huonker M, Stahl F. Free plasma catecholamines in spinal cord injured 447 
persons with different injury levels at rest and during exercise. J Autonom Nerv Syst. 448 
1998;68:96-100. 449 
32. Segal JL, Brunnemann SR, Gordon SK, Eltorai IM. The absolute bioavailability of 450 
oral theophylline in patients with spinal cord injury. Pharmacotherapy. 1986; 6(1): 451 
26-29. 452 
33. Skinner TL, Jenkins DG, Coombes JS, Taafe, DR, Leveritt MD. Dose response of 453 
caffeine on 2000-m rowing performance. Med Sci Sports Exerc. 2010;42(3):571-576. 454 
34. Skinner TL, Jenkins DG, Coombes JS, Taafe DR, Leveritt MD. Coinciding exercise 455 
with peak serum caffeine does not improve cycling performance. J Sci Med Sport. 456 
2013;16:54-59. 457 
34.35. Skinner TL, Jenkins, DG, Leveritt MD, McGorm A, Bolam KA, Coombes JS, 458 
Taaffe, DR. Factors influencing serum caffeine concentrations following caffeine 459 
ingestion. J Sci Med Sport. 2014; 17:516-520. 460 
35.36. Spungen AM, Adkins RH, Stewart CA. Factors influencing body composition 461 
in persons with a spinal cord injury: a cross-sectional study. J Appl Physiol. 462 
2003;95:2398-2407. 463 
36.37. Statland BE, Demas TJ. Serum caffeine half-lives. Healthy subjects vs. 464 
patients having alcoholic hepatic disease. Am J Clin Pathol. 1980;73(3):390-393. 465 
37.38. Van Soeren M, Mohr T, Kjaer M Graham TE. Acute effects of caffeine 466 
ingestion at rest in humans with impaired epinephrine responses. J Appl Physiol. 1996; 467 
80: 999-1005. 468 
38.39. Yi C-X, la Fleur SE, Fliers E, Kalsbeek A. The role of the autonomic nervous 469 
liver innervation in the control of energy metabolism. Biochimica et Biophysica Acta. 470 
2010;1802:416-431. 471 
Tables 472 
Table 1. Participants’ characteristics. 473 
 474 
Figures 475 
Figure 1. Schematic of the experimental protocol. 476 
Figure 2. Mean ± SD plasma caffeine concentration following the consumption of 3 mg∙kg-1 477 
caffeine anhydrous (Aa). Individual data from able-bodied participants (Bb), and participants 478 
with paraplegia (Cc) and tetraplegia (Dd) (dotted/bold lines represent individuals with an 479 
ASIA A/B classification). 480 
Figure 3. Plasma adrenaline (a), noradrenaline (b), free fatty acid (Ac), lactate (Bd), glucose 481 
(Ce), noradrenaline (D) and adrenaline (E) concentrations (mean ± SD) following the 482 
consumption of 3 mg∙kg-1 caffeine anhydrous in able-bodied (AB) individuals and individuals 483 
with paraplegia (PARA) and tetraplegia (TETRA). * significant main effect for group; † 484 
significant time by group interaction effect.  485 
 aSignificantly different to baseline values, bsignificantly different to 60 min, csignificantly 486 
different to 90 min. 487 
